Search Results for “EC” – Page 589 – media

Bayer’s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease

The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study
- Source: press.bayer
- 606
- December 15, 2017
Bayer CAD/PAD Company Insight Janssen rivaroxaban
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease

Ionis Pharmaceuticals, Inc. (IONS) announced today that Roche has exercised its option to license IONIS-HTTRx following the completion of a Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in people with Huntington's disease (HD). Roche will now be responsible for all development and commercial activities. IONIS-HTTRx is the first therapy in clinical development designed to target the underlying cause of HD by reducing the production of the toxic mutant huntingtin protein (mHTT). In conjunction with the decision to license IONIS-HTTRx, Ionis earned a $45 million license fee from Roche.
- Source: finance.yahoo
- 479
- December 15, 2017
Clinical Trials Huntington’s Disease IONIS-HTTRx
11 Brilliant Ways Therapists Control Their Holiday Stress

Sometimes even the experts need a little help staying holly and jolly. Research shows holiday season stress can feel insurmountable. No one is immune. Mental health professionals, who are usually helping others manage emotions, put their own advice into practice as the year winds down.
- Source: msn
- 373
- December 15, 2017
holiday season stress Researches
Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer

Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive (M+) advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine kinase inhibitors (TKI) – afatinib* in first-line, followed by second-line osimertinib**as part of standard clinical practice – will be analysed to determine total time on treatment.
- Source: boehringer-ingelheim
- 508
- December 14, 2017
EGFR NSCLC Researches
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome

The U.S. Food and Drug Administration(FDA) expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body. This new indication provides the first FDA-approved therapy specifically to treat EGPA.
- Source: Prnewswire;
- 485
- December 14, 2017
EGPA New Approvals vasculitis
SwipeSense Lands $10.6M to Expand Location-Aware Hospital Apps

SwipeSense, a Chicago-based healthcare technology company has raised a $10.6 million in Series B2 funding led by Eclipse Ventures, with participation from Sandbox Industries and other existing technology and healthcare investors. The company plans to utilize the funding to improve its location-aware apps for healthcare platform, explore new use cases and expand its growing team.
- Source: hitconsultant
- 426
- December 14, 2017
HAIs healthcare Market Views Series
FDA suggests controls on interoperable devices

The final FDA guidance on design consideration and pre-market submission for interoperable medical devices was released on September 6. The demand for these devices is increasing in the healthcare system as our dependence on more rapid and protected interactions between devices grows. This increase presents a need for a parallel increase in adequate FDA regulations for this elaborate device field.
- Source: massdevice
- 562
- December 14, 2017
FDA interoperable medical device Policy
New research suggests ‘Man Flu’ may be real

Contrary to popular belief, and the opinions of many women, men really do suffer from 'man flu,' at least according to a Canadian researcher and his most recent study.
- Source: msn
- 473
- December 14, 2017
man flu Researches
‘Ground-breaking’ new drug gives hope in Huntington’s disease

A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute to Reuters on May 15, 2012. REUTERS/National Human Genome Research Institute/Handout.
- Source: in.reuters
- 569
- December 13, 2017
devastating genetic disease Huntington’s Disease Researches
Picture of Health– Can AI Eye Scan Reveal What Ails You?

The light-sensitive layer found at the back of a person's eyes contains more than just cells that detect shadows and light — it also contains information about the health of a person's entire body. And now, artificial intelligence can glean this information from a single snapshot, new research suggests.
- Source: livescience
- 822
- December 13, 2017
Artificial Intelligence Optical coherence tomography Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.